| Tevimbra (tislelizumab-jsgr) / BeiGene |
ChiCTR2000032825: Clinical trial of Ondo combined with DP combined with tirelizumab in the treatment of stage IIIB-IV lung squamous cell carcinoma |
|
|
| Recruiting | 4 | 25 | China | Four-drug combination therapy: patients were treated with endor, Tislelizumab, Docetaxel, and CISPLATIN. | Xinjiang Medical University Affiliated Oncology Hospital ; Xinjiang Medical University Affiliated Oncology Hospital, Funded by Beigene Shenzhou (Beijing) Biopharmaceutical Technology Co., Ltd | Squamous cell carcinomas | | | | |
ChiCTR2000033239: Study for the Efficacy and Safety of Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy |
|
|
| Not yet recruiting | 4 | 77 | China | Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy | Zhejiang Jinhua Guangfu Tumor Hospital ; None, Beigene | Non small cell lung cancer | | | | |
ChiCTR2000033177: The real world study of tislilizumab in the treatment of locally advanced or metastatic urothelial carcinoma |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab, IV, 200mg, Q3w | Department of Urology, the First Affiliated Hospital of Chongqing Medical University ; The First Affiliated Hospital of Chongqing Medical University, BeiGene (Beijing) Biotechnology Co., Ltd. | Urothelial carcinoma | | | | |
ChiCTR2000040095: Exploratory clinical study of chemotherapy combined with Immune checkpoint inhibitors for locally advanced and distant metastatic penile cancer |
|
|
| Not yet recruiting | 4 | 15 | China | Albumin taxol + Cisplatin + Bleomycin+Tislelizumab Injection | Beijing Chaoyang Huanxing Cancer Hospital ; Beijing Chaoyang Huanxing Cancer Hospital, Beijing Medical Award Foundation, Baiji Shenzhou (Beijing) Biotechnology Co., LTD | Penile cancer | | | | |
ChiCTR2000033441: Tislelizumab plus Gemox in relapsed or refractory patients with cHL |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab plus Gemox | Anhui Provincial Cancer Hospital ; Anhui Provincial Cance Hospital, Self-collected | cHL | | | | |
ChiCTR2000039620: Single-arm, single-center exploratory clinical study of terelizumab injection combined with Antinib hydrochloride capsule in the treatment of unresectable hepatocellular carcinoma |
|
|
| Recruiting | 4 | 30 | China | Tirelizumab injection combined with antinib hydrochloride capsule | The First Affiliated Hospital of Guangxi Medical University ; The First Affiliated Hospital of Guangxi Medical University, Baiji Shenzhou (Beijing) Biological Technology Co. Ltd; Chia Tai Tianqing Pharmaceutical Group Co. Ltd. | Cancer of the liver | | | | |
ChiCTR2000033599: PD-1 monoclonal antibody (tirelizumab) alternative radiotherapy for children with classic Hodgkin's lymphoma: a prospective, one-arm, open-label real-world study |
|
|
| Recruiting | 4 | 40 | China | Intravenous Tislelizumab | Beijing Boren Hospital ; Beijing Boren Hospital, Self-raised | Children's classic Hodgkin's lymphoma | | | | |
ChiCTR2100049944: Tislelizumab plus Gemox in relapsed or refractory patients with ENKTCL |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab in combination with gemcitabine and oxaliplatin | Jiangsu Provincial People's Hospital ; Jiangsu Provincial People's Hospital, Self-collected | ENKTCL | | | | |
TINES, NCT05603065: Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 4 | 32 | RoW | Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy | First Affiliated Hospital Xi'an Jiaotong University | Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
ChiCTR2200056941: Neoadjuvant treatment with Tislelizumab combined with GP regimen for high-risk (T4/N3) locally advanced nasopharyngeal carcinoma：an open-lable clinicaltrial |
|
|
| Not yet recruiting | 4 | 25 | China | Tislelizumab combine with GP regimen | Jiangmen Central Hospital ; Jiangmen Central Hospital, Self financing | Nasopharyngeal carcinoma | | | | |
ChiCTR2100047036: A single-arm, single-center, prospective real-world study of Tislelizumab in the treatment of patients with advanced metastatic or unresectable renal clear cell carcinoma |
|
|
| Recruiting | 4 | 45 | | Nil | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, BeiGene (Beijing) Biotechnology Co., Ltd. | Advanced renal clear cell carcinoma | | | | |
ChiCTR2200056181: Single-arm and exploratory clinical study of lenvatinib, tirelizumab and radiotherapy combined with HAIC in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
|
|
| Recruiting | 4 | 38 | China | Lenvatinib+Tislelizumab+Radiotherapy + Hepatic Artery Infusion Chemotherapy (HAIC) | Zhongshan Hospital Xiamen University ; Zhongshan Hospital Xiamen University, self-funded | Hepatocellular carcinoma | | | | |
PILOT, NCT06357598: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer |
|
|
| Recruiting | 4 | 30 | RoW | Tislelizumab, PD-1 antibody, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), chemotherapeutic drug, Carboplatin or Cisplatin, Surgery | The Affiliated Hospital of Qingdao University | Non-small-cell Lung Cancer (NSCLC) | 12/24 | 12/25 | | |
ChiCTR2000037670: A Multicenter Study of Neoadjuvant Tislelizumab (BGB-A317, anti-PD-1 antibody) combined with Cisplatin and Gemcitabine for cT2-T4aN0M0 Bladder Urothelial Cancer |
|
|
| Not yet recruiting | 4 | 65 | China | Tislelizumab+Gemcitabine+Cisplatin+Radical Cystectomy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ; Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, BeiGene (Beijing) Co., Ltd. | Bladder Urothelial Cancer | | | | |
ChiCTR2100054256: Clinical study of tislelizumab combined with gemcitabine and siggio in the first-line treatment of advanced pancreatic cancer |
|
|
| Recruiting | 4 | 30 | China | Tislelizumab in combination with gemcitabine and Sega | The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital) ; The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Beijing Medical Award Foundation | Advanced pancreatic cancer | | | | |
ChiCTR2200059848: A single-arm, prospective, Phase II clinical study of surufatinib in combination with tislelizumab in advanced colorectal cancer after third-line treatment failure |
|
|
| Not yet recruiting | 4 | 31 | China | Surufatinib+tislelizumab | Anhui Cancer Hospital ; Anhui Cancer Hospital, Self-financing | Colorectal cancer | | | | |
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. |
|
|
| Not yet recruiting | 4 | 312 | NA | HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06003673: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC |
|
|
| Recruiting | 4 | 20 | RoW | neoadjuvant therapy | First Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Resectable | 07/24 | 07/25 | | |
NCT06356675: A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy |
|
|
| Not yet recruiting | 4 | 33 | NA | Tislelizumab, Anlotinib | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Advanced NSCLC | 07/28 | 07/28 | | |
ChiCTR2300071481: The efficacy and safety of recombinant human adenovirus type 5 injection combined with tirelizumab and hepatic arterial infusion chemotherapy (HAIC) in the treatment of advanced primary hepatocellular carcinoma: a multicenter, prospective, one-arm study |
|
|
| Recruiting | 4 | 25 | China | Recombinant Human Adenovirus Type 5 Injection+Tislelizumab Injection +HAIC | Zhongda Hospital Southeast University ; Zhongda Hospital Southeast University, Beijing Health Promotion Association | Advanced primary hepatocellular carcinoma | | | | |
ChiCTR2100051747: The clinical study of Gegen Qinlian Decoction combined with immunotherapy and chemotherapy in treating lung squamous cell carcinoma(LUSC) |
|
|
| Not yet recruiting | 4 | 27 | China | PD-1 monoclonal antibody (Tislelizumab injection), platinum-containing dual-drug treatment and GQT (Gegen Qinlian tablet) | China-Japan Friendship Hospital ; China-Japan Friendship Hospital, BeiGene Biological Technology Co., Ltd | Lung squamous cell carcinoma | | | | |
NCT05580354: Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Not yet recruiting | 4 | 42 | RoW | BCG combined with Tislelizumab | Ruijin Hospital | Non-muscle-invasive Bladder Cancer | 10/24 | 05/25 | | |
ChiCTR2200062653: Clinical study of transformation treatment of tislelizumab combined with albumin paclitaxel and S-1 in patients with unresectable locally advanced and metastatic gastric cancer |
|
|
| Not yet recruiting | 4 | 121 | China | Tislelizumab combined with albumin paclitaxel and S-1 ;Tislelizumab combined with albumin paclitaxel and S-1 | The First Affiliated Hospital of Zhejiang University ; The First Affiliated Hospital of Zhejiang University, Fujian Province Medical Volunteer Association | Gastric cancer | | | | |
NCT05861635: The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression |
|
|
| Recruiting | 4 | 42 | RoW | Disitamab Vedotin combined with Tislelizumab | Wuhan Union Hospital, China | Breast Cancer, Neoadjuvant Therapy | 02/25 | 02/26 | | |
ChiCTR2200058342: A prospective phase II single-arm clinical study on the efficacy and safety of tislelizumab combined with induction chemotherapy + concurrent chemoradiotherapy + maintenance therapy in patients with stage III unresectable non-small cell lung cancer (NSCLC |
|
|
| Recruiting | 4 | 30 | China | Baizean (tislelizumab) - BeiGene, Novartis | Xiamen Humanity Hospital | Lung Cancer;Oncology | | | | |
ChiCTR2000032856: Efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer |
|
|
| Recruiting | 4 | 60 | China | 1. Tislelizumab 200mg, IV, 1 day before radiotherapy, q3w Until the disease progresses / or lasts for 1 year; 2. concurrent chemoradiotherapy. | Suzhou Municipal Hospital ; Suzhou Municipal Hospital, Sponsorship | Locally advanced cervical cancer | | | | |
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement |
|
|
| Not yet recruiting | 4 | 20 | | None | The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation | diffuse large B-cell lymphoma with secondary CNS involvement | | | | |
ChiCTR2200066771: Efficacy and adverse reactions of radiotherapy combined with immunotherapy and chemotherapy in advanced non-small cell lung cancer: a prospective, non-randomized, concurrent, controlled clinical study |
|
|
| Not yet recruiting | 4 | 165 | China | Radiotherapy+Tislelizumab+Paclitaxel liposome+Cisplatin ;radiotherapy+Tislelizumab+Pemetrexed+Cisplatin ;Tislelizumab+Paclitaxel liposome+Cisplatin ;Tislelizumab+Pemetrexed+Cisplatin | Yiyang Center Hospital ; Yiyang Center Hospital, Chen Xiaoping Foundation、Scientific research Project of Hunan Provincial Health Commission、Hospital self-raised | Non-small Cell Lung Cancer | | | | |
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | 1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd. | advanced intrahepatic cholangiocarcinoma | | | | |
ChiCTR2200059190: A multicenter, prospective, one-arm, real-world study of Tirelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 4 | 200 | China | Tislelizumab Injection | Qilu Hospital of Shandong University ; Qilu Hospital of Shandong University, Shandong University Transverse Fund | Esophageal Squamous Cell Carcinoma | | | | |
| Not yet recruiting | 4 | 41 | China | Tislelizumab combined with gemcitabine and cisplatin | Army Medical Center ; Army Medical Center, No | Bladder Cancer | | | | |
| Recruiting | 4 | 56 | | High-dose irradiation plus low-dose radiatlion combined with tislelizumab and lenvatinib | Pingxiang People's Hospital; Pingxiang People's Hospital, Pingxiang People's Hospital | hepatocellular carcinoma | | | | |
ChiCTR2300067495: Chemotherapy combined with Tislelizumab in fertility-preserving treatment of cervical cancer——a Phase II prospective, single arm clinical study |
|
|
| Recruiting | 4 | 10 | China | chemotherapy combined with Tislelizumab | Liaoning Cancer Hospital & Institute ; Liaoning Cancer Hospital & Institute, Hospital finance funding | Cervical Cancer | | | | |
| Completed | 3 | 805 | Europe, RoW | Tislelizumab, BGB-A317, Docetaxel | BeiGene | Non-small Cell Lung Cancer | 08/20 | 01/24 | | |
|
|
|
|
|
|
| Completed | 3 | 360 | RoW | Tislelizumab, BGB-A317, Tevimbra, Paclitaxel, Nab-paclitaxel, Carboplatin | BeiGene | Non-Small Cell Lung Cancer | 09/20 | 04/23 | | |
|
|
|
|
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC |
|
|
| Completed | 3 | 334 | RoW | Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed, Cisplatin or Carboplatin,Pemetrexed | BeiGene | Non-Small Cell Lung Cancer | 10/20 | 04/23 | | |
|
|
|
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer |
|
|
| Active, not recruiting | 3 | 256 | RoW | Tislelizumab, BGB-A317, Placebo, Gemcitabin, Cisplatin | BeiGene | Recurrent or Metastatic Nasopharyngeal Cancer | 03/21 | 06/25 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 649 | Europe, Japan, US, RoW | Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo | BeiGene | Esophageal Squamous Cell Carcinoma (ESCC) | 02/22 | 08/24 | | |
|
|
|
| Completed | 3 | 674 | Europe, Japan, US, RoW | Tislelizumab, BGB-A317, Sorafenib, Nexavar, BAY43-9006 | BeiGene | Hepatocellular Carcinoma (HCC) | 07/22 | 12/23 | | |
|
|
|
|
|
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma |
|
|
| Active, not recruiting | 3 | 997 | Europe, Japan, US, RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU | BeiGene | Gastric, or Gastroesophageal Junction Adenocarcinoma | 02/23 | 12/24 | | |
|
|
|
NCT04799314: PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT |
|
|
| Not yet recruiting | 3 | 132 | RoW | PD-1 Inhibitor Tislelizumab maintenance therapy | Ruijin Hospital | Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy | 04/23 | 04/24 | | |
RATIONALE-312, NCT04005716: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer |
|
|
| Completed | 3 | 457 | RoW | Tislelizumab, Carboplatin /Cisplatin, Etoposide, Carboplatin / Cisplatin, Etoposide | BeiGene | Small Cell Lung Cancer | 04/23 | 12/23 | | |
NCT06441110: Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 3 | 76 | RoW | Tislelizumab in Combination with Bacillus Calmette-Guérin | Fujian Medical University Union Hospital | Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study, Treatment Outcome, Neoplasm Recurrence, Local | 06/25 | 06/35 | | |
NCT04789434: PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT |
|
|
| Recruiting | 3 | 94 | RoW | PD-1 Inhibitor Tislelizumab maintenance therapy | Ruijin Hospital | Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy | 07/23 | 07/24 | | |
NCT05346952: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). |
|
|
| Recruiting | 3 | 390 | RoW | TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Non-squamous Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT06177301: Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC |
|
|
| Recruiting | 3 | 266 | RoW | Tislelizumab combined with GX, Tislelizumab combined with GP | Fudan University | Nasopharyngeal Carcinoma | 12/26 | 12/27 | | |
RATIONALE-310, NCT03967977: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma |
|
|
| Recruiting | 3 | 420 | RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin | BeiGene | Urothelial Carcinoma | 06/27 | 06/27 | | |
NCT06206733: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma |
|
|
| Recruiting | 3 | 780 | RoW | ASKB589, Oxaliplatin, Capecitabine, Tislelizumab, Placebo | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 12/26 | 12/28 | | |
| Recruiting | 3 | 134 | RoW | albumin paclitaxel, cispatin, tislelizumab | Lai-ping Zhong, Sun Yat-sen University, Fudan University, Central South University, Fujian Medical University | Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma | 12/26 | 12/28 | | |
| Active, not recruiting | 3 | 450 | RoW | Tislelizumab, BGB-A317, Placebo | Sun Yat-sen University, Cancer Hospital of Guizhou Province, Hunan Cancer Hospital, Wuzhou Red Cross Hospital, Affiliated Hospital of Guangdong Medical University | Nasopharyngeal Carcinoma | 05/26 | 05/28 | | |
NCT06364904: An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. |
|
|
| Not yet recruiting | 3 | 210 | RoW | Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib, Tislelizumab, Cisplatin, Gemcitabine | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Bladder Cancer | 04/27 | 04/29 | | |
| Not yet recruiting | 3 | 717 | Europe | Tislelizumab, Blood sampling, Placebo | Gustave Roussy, Cancer Campus, Grand Paris, BeiGene, C2i Genomics | Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue Sarcoma | 05/28 | 04/29 | | |
NCT06383780: Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. |
|
|
| Recruiting | 3 | 90 | RoW | GP combined with Tislelizumab, TPC combined with Tislelizumab | XIANG YANQUN | Nasopharyngeal Carcinoma | 05/27 | 05/29 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma |
|
|
| Not yet recruiting | 3 | 202 | NA | Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Classic Hodgkin Lymphoma | 06/26 | 07/29 | | |
| Terminated | 3 | 377 | RoW | Tislelizumab, Docetaxel, Sitravatinib | BeiGene, BeiGene, Ltd. | Non-Small Cell Lung Cancer (NSCLC) | 12/23 | 12/23 | | |
JAB-21822 3002, NCT06416410: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation |
|
|
| Not yet recruiting | 3 | 392 | NA | JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin | Jacobio Pharmaceuticals Co., Ltd. | Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer | 09/26 | 02/27 | | |
| Enrolling by invitation | 3 | 300 | RoW | Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007 | BeiGene | Advanced Malignancies | 12/26 | 12/26 | | |
NCT06017583: Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 48 | RoW | Tislelizumab, Capecitabine, Oxaliplatin, SIB-IMRT, IMRT | Yong Zhang,MD | Rectal Neoplasms | 08/24 | 08/26 | | |
| Recruiting | 3 | 123 | RoW | Tislelizumab, BGB-A317, Salvage Chemotherapy | BeiGene | Classical Hodgkin Lymphoma | 09/24 | 03/25 | | |
NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 3 | 570 | RoW | TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Squamous Non-Small Cell Lung Carcinoma | 10/24 | 10/25 | | |
ChiCTR2000035665: A Phase III, Prospective, Multicenter, Randomized, Controlled Trial of Neoadjuvant Transcatheter Arterial Chemoembolization (TACE) plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 524 | | neoadjuvant TACE plus islelizumab followed by adjuvant islelizumab treatment ;4 cycles neoadjuvant SOX treatment followed by 4 cycles adjuvant SOX treatment | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Major Clinical Research Project of Shanghai Shenkang Hospital Development Center | Gastric cancer | | | | |
RATIONALE-311, NCT03957590: Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC |
|
|
| Active, not recruiting | 3 | 370 | RoW | Tislelizumab, BGB-A317, Placebo, Paclitaxel, Cisplatin, Radiotherapy | BeiGene | Esophageal Squamous Cell Carcinoma (ESCC) | 11/24 | 12/24 | | |
| Recruiting | 3 | 396 | RoW | AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel | Akeso | Advanced Squamous Non Small Cell Lung Cancer | 12/24 | 12/25 | | |
ChiCTR2200064384: Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 50 | | 1 | The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Nanchang University | hepatocellular carcinoma | | | | |
PREVENT-2, NCT05910970: Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation |
|
|
| Not yet recruiting | 3 | 200 | RoW | Adjuvant tislelizumab plus lenvatinib, Adjuvant tislelizumab | Guangxi Medical University | Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 662 | US | Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembrolizumab, KEYTRUDA, Placebo | BeiGene | Non-small Cell Lung Cancer, NSCLC | 04/26 | 10/26 | | |
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 453 | RoW | Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin | BeiGene | Non Small Cell Lung Cancer | 06/25 | 11/25 | | |
| Not yet recruiting | 3 | 650 | NA | QL1706, PSB205, Tilesizumab, BGB-108 | Qilu Pharmaceutical Co., Ltd. | Lung Cancer | 06/25 | 06/25 | | |
NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 642 | RoW | AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel | Akeso | Locally Advanced or Metastatic NSCLC | 08/25 | 11/26 | | |
NCT06031597: Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy |
|
|
| Not yet recruiting | 3 | 105 | NA | radiotherapy, Platinum-Based Drug, Cisplatin, Immunotherapy, Nivolumab, Atezolizumab, Durvalumab, Pembrolizumab, Tislelizumab, Sugemalimab, Sintilimab, Camrelizumab, Immunotherapeutic Agent | Zhejiang Cancer Hospital | Non-small Cell Lung Cancer Stage III | 12/25 | 12/25 | | |
HARMONIA, NCT05207709: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype |
|
|
| Recruiting | 3 | 456 | Europe, US | Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab | SOLTI Breast Cancer Research Group, Novartis, Alliance Foundation Trials, LLC. | Metastatic Breast Cancer | 03/26 | 03/27 | | |
NCT05919030: A Study of Chemoradiation in Combination With Tislelizumab as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 155 | RoW | Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin, Nab paclitaxel | Renmin Hospital of Wuhan University | Esophageal Squamous Cell Carcinoma | 07/26 | 07/27 | | |
NCT05823311: Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma |
|
|
| Recruiting | 3 | 80 | RoW | Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Tumor Hospital of Xinjiang Medical University | Advanced Cholangiocarcinoma | 12/26 | 12/28 | | |
| Terminated | 3 | 63 | US, RoW | Tislelizumab, BGB-A317, Durvalumab, Ociperlimab, BGB-A1217 | BeiGene, BeiGene, Ltd. | Non Small Cell Lung Cancer | 10/23 | 10/23 | | |
|
NCT05564338: Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma |
|
|
| Withdrawn | 3 | 684 | NA | Sitravatinib, Tislelizumab, sitravatinib-matching placebo, tislelizumab-matching placebo | BeiGene | Hepatocellular Carcinoma | 04/27 | 04/28 | | |
NCT05342792: Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 556 | RoW | PD-1 antibody, Tislelizumab, Capecitabine | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University, Affiliated Cancer Hospital of Guizhou Medical University, Cancer Hospital of Guangxi Medical University, First People's Hospital of Foshan, Chongqing University Cancer Hospital, Hubei Cancer Hospital, Hunan Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Fifth Affiliated Hospital, Sun Yat-Sen University, Shandong Provincial Hospital | Nasopharyngeal Carcinoma | 06/27 | 06/29 | | |
NCT04997837: Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma |
|
|
| Recruiting | 3 | 433 | RoW | PD-1 inhibitor, Oxaliplatin, Capecitabine, Tegafur-gimeracil-oteracil potassium, 5-FU, Radiotherapy, Chemotherapy | Fudan University | Gastric Cancer | 07/27 | 10/27 | | |
| Recruiting | 3 | 500 | Europe, US, RoW | Zanubrutinib, BGB-3111, Tislelizumab, BGB-A317 | BeiGene | B-cell Malignancies | 11/27 | 12/28 | | |
AdvanTIG-306, NCT05791097: Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. |
|
|
| Withdrawn | 3 | 980 | NA | Ociperlimab, WCD118, Placebo, Tislelizumab, VDT482, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel | Novartis Pharmaceuticals | Non-small Cell Lung Cancer (NSCLC) | 12/27 | 12/27 | | |
AIRES, ChiCTR2100045651: Adjuvant Immunotherapy for Resected Esophageal Squamous Cell Carcinoma with High Risk for Recurrence: a Open-Label, Randomized, Controlled Phase III Trial |
|
|
| Recruiting | 3 | 220 | China | Platinum-Based Doublets (2 Cycles) Combination with Tislelizumab to One Year ;Tislelizumab Only to One Year | Cancer Hospital, Chinese Academy of Medical Sciences ; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing Medical Award Foundation and Beigene Biological Technology Co., Ltd | Esophageal cancer | | | | |
REDUCTION-I, NCT05582265: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 537 | RoW | Tislelizumab（neoadjuvant）, Cisplatin （neoadjuvant）, Nab-paclitaxel （neoadjuvant）, Surgical resection, Cisplatin（adjuvant）, Tislelizumab（adjuvant）, Radiation, Carboplatin (neoadjuvant）, Carboplatin (adjuvant） | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Shenzhen Sixth People's Hospital | Head and Neck Squamous Cell Carcinomas | 10/28 | 10/30 | | |
NCT05809336: Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors |
|
|
| Completed | 2/3 | 172 | RoW | Inosine 0.2g orally 3 times/day, Camrelizumab for injection, Sintilimab injection, Penpulimab injection, Tislelizumab injection, Pembrolizumab injection, Toripalimab, Atezolizumab, chemotherapy/targeting, PD-1/PD-L1 inhibitor ,chemotherapy/targeting | Beijing Friendship Hospital | Advanced Solid Tumor | 10/22 | 10/22 | | |
ChiCTR2000033625: PD-1 monoclonal antibody (tirelizumab) monotherapy or combination regimen for the treatment of extranodal NK/T cell lymphoma in children: a prospective, open-label real-world study |
|
|
| Recruiting | 2/3 | 20 | China | Intravenous tislelizumab | Beijing Boren Hospital ; Beijing Boren Hospital, Self-raised | Extranodal NK/T cell lymphoma in children | | | | |
NCT05409417: Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status |
|
|
| Recruiting | 2/3 | 40 | RoW | Experimental drug, Tilelizumab combined with chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 02/24 | 09/24 | | |
NCT06312982: A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study |
|
|
| Recruiting | 2/3 | 375 | RoW | Tislelizumab | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Peking University Cancer Hospital & Institute, CHINA-JAPEN FRIENDSHIP HOSPITAL, Peking Union Medical College Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Changhai Hospital, RenJi Hospital, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Shandong Provincial Hospital, Zhongnan Hospital of Wuhan University & Second Clinical Hospital of Wuhan University, The First Affiliated Hospital of Zhengzhou University, West China School of Medicine and West China Hospital, Sichuan University, Sichuan Academy of Medical Sciences, The Sixth Affiliated Hospital, Sun Yat-sen University, The First Hospital of Jilin University, First Hospital of China Medical University, Army Medical Center of PLA, The First Affiliated Hospital of Anhui Medical University | Locally Advanced Rectal Carcinoma | 12/26 | 12/26 | | |
PKUCH-R09, NCT06443671: Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2/3 | 132 | RoW | CapeOX, Fruquintinib and Tislelizumab combined with mCapeOX | Peking University Cancer Hospital & Institute | Rectal Cancer | 06/26 | 06/28 | | |
NCT04973306: Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC |
|
|
| Recruiting | 2/3 | 176 | RoW | Neoadjuvant Chemoradiotherapy, Tislelizumab, anti-PD-1 antibody, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) | Shanghai Zhongshan Hospital, Beijing Cancer Hospital, Shanghai Chest Hospital, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Zhongshan Hospital, Fudan University (Xiamen Branch), Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Tongji Hospital, Sun Yat-sen University, Shanghai Fifth People's Hospital | Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | 07/24 | 07/27 | | |
NCT05699655: Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | Tislelizumab, apatinib, oxaliplatin, S-1 | Fujian Cancer Hospital | Immunotherapy Gastrict Cancer | 03/25 | 04/27 | | |
NCT05325528: Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases |
|
|
| Recruiting | 2/3 | 40 | RoW | Tislelizumab in Combination with Oxaliplatin and Tegafur | Zhejiang University | Liver Metastases | 08/25 | 12/25 | | |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
ACTRN12622000207718p: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma |
|
|
| Not yet recruiting | 2 | 35 | | | Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG) | Hodgkin Lymphoma | | | | |
ACTRN12621000273886: Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer |
|
|
| Recruiting | 2 | 135 | | | The University of Sydney, Australian Government - Medical Research Future Fund (MRFF) | Endometrial Cancer | | | | |
ACTRN12622000207718: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 35 | | | Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG) | Hodgkin Lymphoma | | | | |
ChiCTR2100054451: Phase II clinical study of tislelizumab combined with R-CHOP in the first-line treatment of unspecified EBV-positive diffuse large B-cell lymphoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab combined with R-CHOP | Fudan University Cancer Hospital ; Fudan University Cancer Hospital, BeiGene | EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) | | | | |
2018-002492-17: Evaluation of a Treatment with tislelizumab and zanubrutinib in patients with a Richter Transformation. Bewertung einer Behandlung mit Tislelizumab und Zanubrutinib bei Patienten mit einer Richter-Transformation. |
|
|
| Not yet recruiting | 2 | 48 | Europe | Tislelizumab, Zanubrutinib, BGB-A317, BGB-3111, Concentrate and solvent for concentrate for solution for infusion, Capsule, Tislelizumab, Zanubrutinib | Universität zu Köln, BeiGene Ltd. | Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 33 | RoW | Apatinib Combined With Tislelizumab and Chemotherapy, Combined therapy | Renmin Hospital of Wuhan University | Advanced Gastric Adenocarcinoma | 03/23 | 01/24 | | |
NCT04541277: Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy |
|
|
| Recruiting | 2 | 55 | RoW | Tislelizumab, Decitabine, Azacitidine, Cytarabine, Idarubicin, Aclarithromycin, Recombinant Human Granulocyte Colony Stimulating Factor, Pegylated Recombinant Human Granulocyte Colony Stimulating Factor | Chinese PLA General Hospital | Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease | 08/21 | 08/22 | | |
ChiCTR2000040139: A prospective study of the efficacy and safety of tislelizumab combined with regorafenib in patients with unresectable or recurring cholangiocarcinoma after resection |
|
|
| Not yet recruiting | 2 | 42 | China | regorafenib + tislelizumab | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Association of Cancer Prevention and Treatment | Cholangiocarcinoma | | | | |
NCT04498793: Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 55 | RoW | Tislelizumab, Nab paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital Xi'an Jiaotong University, Wuhan Union Hospital, China, Beijing Huanxing Cancer Hospital | HER2-negative Breast Cancer | 12/21 | 12/22 | | |